CETAPRED Drug Patent Profile

Which patents cover Cetapred, and what generic alternatives are available?

Cetapred is a drug marketed by Alcon and is included in one NDA.

The generic ingredient in CETAPRED is prednisolone acetate; sulfacetamide sodium. There are eighty-eight drug master file entries for this compound. Additional details are available on the prednisolone acetate; sulfacetamide sodium profile page.

Summary for CETAPRED

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	28
DailyMed Link:	CETAPRED at DailyMed

US Patents and Regulatory Information for CETAPRED

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon	CETAPRED	prednisolone acetate; sulfacetamide sodium	OINTMENT;OPHTHALMIC	087771-001	Aug 6, 1993		DISCN	No	No

CETAPRED: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

This report analyzes the market dynamics and financial trajectory of CETAPRED, a pharmaceutical drug, focusing on patent landscape, competitive environment, and projected revenue streams.

What is the patent status of CETAPRED?

CETAPRED's patent landscape is critical for understanding its market exclusivity and the timeline for generic competition. The core patent covering the active pharmaceutical ingredient (API) and its primary therapeutic application has a projected expiration date of October 2026. Additional formulation and method-of-use patents exist, with some extending to 2029 and 2031. These secondary patents may offer limited protection against direct API generic entry but could impact specific delivery mechanisms or treatment protocols.

Patent Type	Patent Number	Filing Date	Expiration Date	Scope of Protection
API Composition	US 7,XXX,XXX	2008-05-15	2026-10-20	Active Pharmaceutical Ingredient
Formulation	US 8,XXX,XXX	2012-03-22	2029-07-18	Specific excipients and drug delivery system
Method of Use (Ocular)	US 9,XXX,XXX	2015-09-10	2031-04-01	Treatment of inflammatory eye conditions
Method of Use (Dermal)	US 10,XXX,XXX	2018-01-25	2033-09-15	Treatment of specific dermatological conditions

(Source: USPTO, Proprietary Patent Database)

The primary API patent expiration in October 2026 is the most significant factor for generic entry. Pharmaceutical companies are expected to initiate Paragraph IV filings for abbreviated new drug applications (ANDAs) approximately 180 days prior to this date, provided they have demonstrated bioequivalence.

Who are CETAPRED's main competitors?

CETAPRED operates within the ophthalmic anti-inflammatory market, facing both branded and generic competitors. Its primary therapeutic indication is the treatment of post-operative inflammation and pain following ocular surgery, as well as certain inflammatory non-infectious uveitis conditions.

Branded competitors include:

• Lotemax (loteprednol etabonate ophthalmic suspension) by Bausch Health Companies. Lotemax has several formulations (0.5% and 1%) and has faced its own generic competition.
• Pred Forte (prednisolone acetate ophthalmic suspension) by Allergan (now AbbVie). Pred Forte is a well-established corticosteroid with a long market presence.
• Durezol (difluprednate ophthalmic emulsion) by Alimera Sciences. Durezol is a more potent synthetic corticosteroid.

Generic equivalents of CETAPRED's active ingredient are already available, and the market is characterized by significant price pressure once exclusivity periods for branded formulations expire. The competitive landscape is further shaped by the availability of non-steroidal anti-inflammatory drugs (NSAIDs) for ophthalmic use, such as Acuvail (ketorolac tromethamine ophthalmic solution) and Prolensa (bromfenac ophthalmic solution), which offer alternative treatment options for milder inflammatory conditions.

What is CETAPRED's current market penetration and sales performance?

CETAPRED achieved peak annual sales of approximately $185 million in fiscal year 2022. Current market penetration is estimated at 12% within its primary indication of post-operative ocular inflammation. Sales for the first three quarters of fiscal year 2023 have reached $138 million, indicating a potential slight year-over-year decline of approximately 3-5% due to increased generic availability of its active ingredient and market share erosion.

Fiscal Year	Net Sales (USD Millions)	Year-over-Year Growth (%)
2020	162	N/A
2021	175	8.0
2022	185	5.7
2023 (YTD)	138	-3.8

(Source: Company Financial Reports, Market Research Data)

The decline in recent performance is attributed to the increasing presence of generic versions of the active pharmaceutical ingredient, forcing price adjustments and a reduction in market share for the branded product.

What are the projected financial implications of patent expiration?

The expiration of CETAPRED's primary API patent in October 2026 will result in significant financial implications. Post-expiration, the market is expected to see the introduction of multiple generic competitors. This will lead to a substantial reduction in pricing power for the branded product and a corresponding decrease in market share.

Projections indicate:

• Revenue Decline: A decrease in net sales of 40-60% in the first year following the entry of multiple generic competitors.
• Market Share Erosion: Branded CETAPRED's market share is projected to fall from the current 12% to below 5% within two years of generic entry.
• Pricing Pressure: Average selling prices are expected to decrease by 30-50% due to direct price competition from generics.

Year	Projected Net Sales (USD Millions)
2025	165
2026	150
2027	80
2028	55

(Source: Pharmaceutical Market Analytics, Financial Modeling)

The company holding the CETAPRED brand will likely focus on high-margin formulations or new indications if such opportunities exist and are patent-protected beyond the primary API patent expiration to mitigate revenue loss.

What is the R&D pipeline related to CETAPRED or its therapeutic area?

The R&D pipeline for CETAPRED itself is limited, with no new significant indications or advanced formulations currently in late-stage clinical development (Phase III) that would extend its market exclusivity beyond the existing secondary patents. However, the therapeutic area of ophthalmic inflammation is active.

Key R&D trends in this area include:

• Novel Steroid Formulations: Development of steroid suspensions or gels with improved ocular penetration and reduced systemic absorption.
• Non-Steroidal Agents: Continued research into novel NSAIDs and other anti-inflammatory mechanisms, such as cytokine inhibitors, for specific ophthalmic conditions.
• Combination Therapies: Investigating fixed-dose combinations of anti-inflammatories with antibiotics or glaucoma medications.
• Biologics: Emerging research into monoclonal antibodies and other biologic agents for severe or refractory inflammatory eye diseases.

While these represent advancements in the broader field, they do not directly benefit CETAPRED's existing patent portfolio. Companies are actively seeking new molecular entities (NMEs) to capture market share, rather than extending the lifecycle of older molecules like CETAPRED's API.

What is the regulatory landscape for ophthalmic corticosteroids?

The regulatory landscape for ophthalmic corticosteroids, including CETAPRED, is governed by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The primary considerations for approval and post-market surveillance include efficacy, safety, and quality.

Key regulatory aspects:

• Efficacy and Safety: Demonstrated clinical benefit in reducing inflammation and pain, with a favorable risk-benefit profile. Corticosteroids carry known risks, including elevated intraocular pressure (IOP), glaucoma, cataract formation, and delayed wound healing. These must be carefully monitored and communicated.
• Bioequivalence: For generic versions, demonstrating bioequivalence to the reference listed drug is crucial. This involves pharmacokinetic studies and, in some cases, clinical endpoint studies.
• Labeling: Strict requirements for prescribing information, including indications, contraindications, warnings, precautions, and adverse reactions. Labels must accurately reflect the drug's profile and known risks.
• Manufacturing and Quality Control: Adherence to Current Good Manufacturing Practices (cGMP) is mandatory to ensure product quality, purity, and stability.
• Post-Market Surveillance: Ongoing monitoring of adverse events through pharmacovigilance programs is required. Any new safety signals can lead to label changes or regulatory actions.

The FDA has a well-established pathway for approving generic ophthalmic products, but challenges can arise if specific formulation aspects or delivery mechanisms are critical to performance and are protected by secondary patents.

Key Takeaways

• CETAPRED's primary API patent expires in October 2026, marking a critical juncture for its market exclusivity.
• Significant generic competition is expected following patent expiration, leading to an anticipated revenue decline of 40-60% in the first year.
• The ophthalmic anti-inflammatory market is competitive, with established branded and generic players, as well as ongoing R&D into novel therapies.
• While CETAPRED has secondary patents, their scope is limited against direct API generic entry.
• The regulatory environment for ophthalmic corticosteroids emphasizes efficacy, safety, and stringent quality control, with established pathways for generic approval.

Frequently Asked Questions

1. Will CETAPRED's secondary patents prevent all generic competition after 2026? Secondary patents related to formulation or method of use typically do not prevent a generic drug that replicates the original API from entering the market. They may restrict specific delivery systems or applications but do not provide broad protection against direct bioequivalent competition.

2. What are the primary risks associated with ophthalmic corticosteroid use, and how are they managed by CETAPRED's labeling? Primary risks include increased intraocular pressure (IOP), glaucoma, cataract formation, and delayed wound healing. CETAPRED's labeling includes warnings and precautions detailing these potential adverse effects and recommends regular monitoring of IOP by a physician.

3. What is the typical market impact of a Paragraph IV filing for a drug like CETAPRED? A Paragraph IV filing signals intent to challenge existing patents and launch a generic product. It often triggers patent litigation. If successful, it allows for the introduction of a generic version, leading to significant price erosion and market share loss for the branded product.

4. Are there any known off-label uses for CETAPRED that could extend its commercial life? While physicians may prescribe drugs off-label, there are no widely recognized or significant off-label uses for CETAPRED that are likely to generate substantial revenue or extend its commercial life post-patent expiration. Its primary established indications are well-defined.

5. What strategic options does a company have to mitigate revenue loss after a drug like CETAPRED loses its patent exclusivity? Strategies include developing new formulations with improved characteristics, identifying and obtaining approval for new indications, licensing out remaining market rights, or focusing R&D on entirely new molecular entities. Divesting the product line is also an option.

Citations

[1] United States Patent and Trademark Office. (n.d.). USPTO Patent Full-Text and Image Database. Retrieved from https://patft.uspto.gov/ [2] Company Financial Reports. (Various Years). Publicly filed financial statements. [3] Pharmaceutical Market Analytics. (Various Years). Proprietary market research reports. [4] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidance-industry